Published in Antiviral Res on November 01, 2013
Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis (2014) 1.36
Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep (2014) 1.02
Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS (2014) 0.97
Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS (2014) 0.96
Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs (2015) 0.90
Pre-exposure prophylaxis in Southern Africa: feasible or not? J Int AIDS Soc (2015) 0.83
ARV-based HIV prevention for women - where we are in 2014. J Int AIDS Soc (2014) 0.82
A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. PLoS One (2016) 0.76
Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide. BMC Infect Dis (2016) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Res Hum Retroviruses (2015) 0.75
Non-Antiretroviral Microbicides for HIV Prevention. AIDS Rev (2016) 0.75
Pipeline for contraceptive development. Fertil Steril (2016) 0.75
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev (2012) 1.37
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res (2013) 1.12
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses (2013) 1.04
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci (2011) 1.01
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci (2007) 0.97
Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res (2010) 0.94
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures. J Acquir Immune Defic Syndr (2015) 0.89
Measuring macrodiffusion coefficients in microbicide hydrogels via postphotoactivation scanning. Biomacromolecules (2008) 0.87
Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release (2012) 0.87
Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. Mol Pharm (2010) 0.85
Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm (2011) 0.84
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials (2011) 0.84
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine. Drug Deliv Transl Res (2011) 0.83
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm (2011) 0.82
Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int J Pharm (2010) 0.81
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81
Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Deliv Transl Res (2011) 0.81
Intravaginal flux controlled pump for sustained release of macromolecules. Pharm Res (2014) 0.81
Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res (2013) 0.79
Chemorheology of phenylboronate-salicylhydroxamate crosslinked hydrogel networks with a sulfonated polymer backbone. Macromolecules (2008) 0.79
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS (2016) 0.79
Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J Pharm Sci (2013) 0.78
Site-specific cross-linking of proteins through tyrosine hexahistidine tags. Bioconjug Chem (2005) 0.77
Specific covalent immobilization of proteins through dityrosine cross-links. Langmuir (2006) 0.77
Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies. Antiviral Res (2013) 0.77
Development of a UC781 releasing polyethylene vinyl acetate vaginal ring. Drug Deliv Transl Res (2012) 0.76
Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Eur J Pharm Biopharm (2013) 0.75
An update on second-generation devices for endometrial ablation. Expert Rev Med Devices (2005) 0.75
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. J Biomed Mater Res B Appl Biomater (2012) 0.75